Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors.
about
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Exenatide once weekly: opportunities in the primary care setting.Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.Emerging gliptins for type 2 diabetes.Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.Incretins: clinical perspectives, relevance, and applications for the primary care physician in the treatment of patients with type 2 diabetes mellitusA potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents.A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy.Treatment of streptozotocin-induced diabetic rats with alogliptin: effect on vascular and neural complications.Diabetes-related alterations in the enteric nervous system and its microenvironment.Mechanisms of current therapies for diabetes mellitus type 2The efficacy and safety of liraglutide.Recent patents of dipeptidyl peptidase IV inhibitors.Update on incretin hormones.Linagliptin: a review of its use in the management of type 2 diabetes mellitus.Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study.The increasing role of primary care physicians in caring for patients with type 2 diabetes mellitus.Effect of stem cell therapy on induced diabetic keratopathy in albino rat.Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
P2860
Q22241288-49D8971A-69D5-4BEC-BC6F-D5652C80F41AQ30431639-D4B1DE2C-9029-485F-85BE-EF87638EF8B8Q30643065-75BDA7B6-4C97-4004-9AF4-061959F2894DQ34347884-55A5AB55-18DE-413E-BE64-112187C5E224Q34353892-2C74424C-1E16-4874-BFBC-46E3224F4994Q34374350-F1161D93-E9CA-4E1A-87AC-BD0825559066Q34441309-C966C33D-EA21-4F39-8FA5-DDF64293CD6DQ35102138-6B7A1957-9DB9-4480-833E-83F512423C37Q35125198-5490457E-9AF9-470A-A81F-D41F65C7A838Q35988135-E22E2B1A-5C43-47B2-AA58-3AB4D70B8620Q37180829-10FEC1F4-7127-4C05-9651-33A9EF70F302Q37939660-97C875AA-E4AF-4A8F-AE92-E343BA948F3DQ37948110-75111362-A648-4899-B20F-4A654DFEBE3DQ38006504-49504708-983E-4382-9918-7597FBFE48B4Q38036742-E58CF757-9522-4833-A1B2-7D4D9B754F2EQ39156623-735557E4-17FB-4A16-BBED-29579944930DQ42336300-DA672305-5D66-4D11-BE62-A62916E452EBQ42867737-63617006-18DE-47B6-9CBB-68F25BFD6339Q57412648-B71C4AE0-11F7-42DB-9423-137B2A228C56
P2860
Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Incorporating incretin-based t ...... ptidyl peptidase 4 inhibitors.
@ast
Incorporating incretin-based t ...... ptidyl peptidase 4 inhibitors.
@en
Incorporating incretin-based t ...... ptidyl peptidase 4 inhibitors.
@nl
type
label
Incorporating incretin-based t ...... ptidyl peptidase 4 inhibitors.
@ast
Incorporating incretin-based t ...... ptidyl peptidase 4 inhibitors.
@en
Incorporating incretin-based t ...... ptidyl peptidase 4 inhibitors.
@nl
prefLabel
Incorporating incretin-based t ...... ptidyl peptidase 4 inhibitors.
@ast
Incorporating incretin-based t ...... ptidyl peptidase 4 inhibitors.
@en
Incorporating incretin-based t ...... ptidyl peptidase 4 inhibitors.
@nl
P2860
P356
P1476
Incorporating incretin-based t ...... ptidyl peptidase 4 inhibitors.
@en
P2093
Jaime A Davidson
P2860
P304
P356
10.4065/MCP.2010.0469
P407
P433
P577
2010-11-24T00:00:00Z